Armata Pharmaceuticals, Inc.
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
WA
Business Address
5005 MCCONNELL AVE, LOS ANGELES, CA, 90066
Mailing Address
5005 MCCONNELL AVE, LOS ANGELES, CA, 90066
Phone
310-665-2928
Fiscal Year End
1231
EIN
911549568
Financial Overview
FY2025
$9.29M
Cash & Equivalents
$-0.52
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 25, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | March 11, 2026 | View on SEC |
Annual Reports
10-K
March 25, 2026
- AP-SA02 demonstrated an 88% response rate in treating Staphylococcus aureus blood infections compared to 58% for standard antibiotics.
- FDA granted 'Fast Track' status to AP-SA02, providing a faster review process and five years of potential market exclusivity.
Material Events
8-K
Financial Distress
March 25, 2026
High Impact
- Debt maturity extended to June 30, 2027, providing critical operational runway.
- Focused R&D pipeline targeting S. aureus and P. aeruginosa treatments.
8-K
Other
March 19, 2026
High Impact
- AP-SA02 received Qualified Infectious Disease Product (QIDP) status from the FDA, offering priority review and an extra five years of market exclusivity.
- The FDA confirmed study data is sufficient to move AP-SA02 into a Phase 3 clinical trial, with plans to start in the second half of 2026.
Related Companies
Companies in the same industry (SIC: 2836)
Scinai Immunotherapeutics Ltd.
SCNI
Biological Products, (No Diagnostic Substances)
Genenta Science S.p.A.
GNTA
Biological Products, (No Diagnostic Substances)
Greenland Mines Ltd
GRML
Biological Products, (No Diagnostic Substances)
Kymera Therapeutics, Inc.
KYMR
Biological Products, (No Diagnostic Substances)
Innate Pharma SA
IPHA
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.